Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on discovering and developing small-molecule medicines for neurological and psychiatric disorders. Its lead program, RAP-219, is being advanced for focal onset seizures, supported by the company’s RAP technology platform and licensed neuroscience assets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaSmall-molecule drug candidates being advanced through preclinical and clinical development.
Internal discovery platform used to identify and develop RAP-targeted therapies.
In-licensed TARPγ8 and nAChR programs and related know-how from Janssen.
External CRO, CMO, and clinical trial services used to advance product candidates.
Asiakkaat
Rapport does not yet sell commercial products; its near-term counterparties are clinical investigators, contract research organizations, contract manufacturers, and specialized clinical partners that support development. If approved, its therapies would be used by patients with focal onset seizures and potentially other neurological or psychiatric disorders, with reimbursement decisions made by payors and adoption driven by neurologists and other prescribers.
CROs, CMOs, and trial vendors that provide preclinical, clinical, and manufacturing services.
Hospitals and research sites that enroll patients and execute RAP-219 studies.
Patients with focal onset seizures who would be treated if RAP-219 is approved.
Neurologists and other specialists who would evaluate efficacy, safety, and convenience.
Commercial and government payors that determine coverage and reimbursement.
Strategia
The company’s strategy is to use its RAP platform to build a pipeline of precision neuroscience medicines, with RAP-219 as the lead asset. It also relies on external partners and licensed intellectual property to accelerate development while preserving flexibility to add new product candidates over time.
Clinical data are the main value driver for a pre-commercial biotech.
A broader pipeline reduces single-asset dependence and supports long-term growth.
Clinical and future commercial supply depend on reliable CRO/CMO execution.
Maantiede
Rapport is headquartered in the United States and conducts its business primarily through U.S.-based corporate, research, and clinical development activities. Its operational footprint is shaped by where it can source scientific talent, run clinical trials, and contract with specialized vendors; no country-level revenue disclosure is available because the company is pre-commercial.
Riskit
Rapport faces the typical risks of a clinical-stage biotech: uncertain clinical outcomes, regulatory risk, and the need for substantial future capital. Because it has no approved products, its business also depends on successful IP protection, outsourced manufacturing, and eventual reimbursement and market acceptance if any candidate is commercialized.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
RAP-219 and future candidates may not demonstrate sufficient efficacy or safety.
Kohdistuu: Lead asset RAP-219
- Capital dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has no product revenue and will need future financing to fund R&D.
Kohdistuu: Corporate funding runway
- Manufacturing and supply chain executionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercial-scale drug substance and drug product processes are still being developed.
Kohdistuu: CMOs and supplier network
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Epilepsy and neuroscience markets include large pharma, generics, devices, and surgeries.
Kohdistuu: Focal onset seizures market
- Reimbursement and market accessVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Any approved product must win coverage and reimbursement to achieve adoption.
Kohdistuu: Future commercial products
Kirjanpito
Harkinnanvaraiset erätClinical trial and CMO invoices may lag service delivery, affecting period expense recognition.
Vaikutus: Can shift quarterly R&D expense and prepaid balances
Payments tied to enrollment or deliverables require judgment on when obligations are incurred.
Vaikutus: Affects timing of expense recognition and liabilities
Cash and short-term investments must be measured and disclosed consistently.
Vaikutus: Influences liquidity presentation and interest income
Public-company equity awards are a meaningful non-cash expense for early-stage biotechs.
Vaikutus: Affects operating loss and diluted share count
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
RAPT Therapeutics, Inc.
Pharmaceutical Preparations
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Camp4 Therapeutics Corp
CAMP · Pharmaceutical Preparations
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company focused on RNA-targeting therapeutics designed to increase gene expression and restore healthy protein levels.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Päivitetty: 24.9.2026